Affinity Health Insurance investigated over chloroquine.
According to eNCA, an East Rand health insurance provider has emerged central to the alleged unlawful importation of chloroquine.
Affinity Health is now being investigated by the South African Health Products Regulatory Authority( SAHPRA).
This follows eNCA’s exclusive report last month which revealed several tons of malaria medication had slipped into the country.
Chloroquine has been touted as a COVID-19 treatment but some studies now indicate it may, in fact, cause harm.
Three independent sources have alleged that Affinity Health was dispensing the medication to staff as a COVID-19 preventative measure.
It has been further alleged that the company planned to distribute chloroquine to its network of pharmacies.
According to eNCA, Affinity Health chief executive Murray Hewlett, through his lawyer, declined to comment on the matter.
SAHPRA also declined an interview but it is understood investigators are preparing to pursue the matter as a violation of the Sars Act.
Meanwhile, The World Health Organization is resuming its trial of hydroxychloroquine, the malaria drug backed by President Donald Trump to combat the deadly coronavirus, after temporarily halting research over safety concerns.
Trump disclosed last month he was taking hydroxychloroquine daily to prevent infection from the coronavirus. White House physician Dr. Sean Conley released a memo that said that after discussing evidence for and against hydroxychloroquine with Trump, they concluded “the potential benefit from treatment outweighed the relative risks.”
The U.S. Food and Drug Administration has warned patients against taking chloroquine or hydroxychloroquine to treat Covid-19 outside a hospital or formal clinical trial setting. The agency said it became aware of reports of “serious heart rhythm problems” in patients with the virus who were treated with the drugs